Amgen Inc. AMG.DE · Stock Open Amgen Inc. in new tab
Amgen Inc. Analysis (AMG.DE)
Is Amgen Inc. a good investment? Amgen Inc. (AMG.DE) is currently trading at 325.00 EUR.
In terms of valuation, the stock trades at a P/E ratio of 24.76. This valuation is generally in line with the broader market.
Earnings Schedule: Amgen Inc. is expected to release its next earnings report on July 30, 2026.
For income investors, Amgen Inc. pays a dividend yield of 2.81%. With a payout ratio of 67%, the dividend appears sustainable.
Investor FAQ
Does Amgen Inc. pay a dividend?
Yes, it pays an annual dividend of 9.80 EUR (2.81% yield).
What asset class is Amgen Inc.?
Amgen Inc. is classified as a Stock. You can compare it against 15 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be July 30, 2026. The company currently has a trailing EPS of 12.64.
Company Profile
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
| Year | Total Dividends |
|---|---|
| ▸2027 |
4.80 EUR
|
| June 4, 2027 (estimated) | 2.4021 |
| March 5, 2027 (estimated) | 2.4021 |
| ▸2026 |
8.95 EUR
|
| Dec. 4, 2026 (estimated) | 2.2686 |
| Sept. 4, 2026 (estimated) | 2.2686 |
| June 5, 2026 | 2.2055 |
| March 6, 2026 | 2.2055 |
| ▸2025 |
8.33 EUR
|
| Dec. 12, 2025 | 2.0830 |
| Sept. 12, 2025 | 2.0830 |
| June 6, 2025 | 2.0830 |
| March 7, 2025 | 2.0830 |
| ▸2024 |
7.88 EUR
|
| Dec. 9, 2024 | 1.9692 |
| Sept. 6, 2024 | 1.9692 |
| June 7, 2024 | 1.9692 |
| March 7, 2024 | 1.9692 |
| ▸2023 |
7.46 EUR
|
| Dec. 8, 2023 | 1.8642 |
| Sept. 8, 2023 | 1.8642 |
| June 8, 2023 | 1.8642 |
| March 8, 2023 | 1.8642 |
| ▸2022 |
6.79 EUR
|
| Dec. 8, 2022 | 1.6979 |
| Sept. 8, 2022 | 1.6979 |
| June 8, 2022 | 1.6979 |
| March 8, 2022 | 1.6979 |
| ▸2021 |
6.16 EUR
|
| Dec. 8, 2021 | 1.5404 |
| Sept. 8, 2021 | 1.5404 |
| June 8, 2021 | 1.5404 |
| March 8, 2021 | 1.5404 |
| ▸2020 |
5.60 EUR
|
| Dec. 8, 2020 | 1.4003 |
| Sept. 8, 2020 | 1.4003 |
| June 8, 2020 | 1.4003 |
| March 6, 2020 | 1.4003 |
| ▸2019 |
5.08 EUR
|
| Dec. 6, 2019 | 1.2690 |
| Sept. 6, 2019 | 1.2690 |
| June 7, 2019 | 1.2690 |
| March 8, 2019 | 1.2690 |
| ▸2018 |
4.62 EUR
|
| Dec. 7, 2018 | 1.1553 |
| Sept. 7, 2018 | 1.1553 |
| June 8, 2018 | 1.1553 |
| March 8, 2018 | 1.1553 |
| ▸2017 |
4.03 EUR
|
| Dec. 8, 2017 | 1.0065 |
| Sept. 8, 2017 | 1.0065 |
| June 8, 2017 | 1.0065 |
| March 8, 2017 | 1.0065 |
| ▸2016 |
3.50 EUR
|
| Dec. 8, 2016 | 0.8752 |
| Sept. 8, 2016 | 0.8752 |
| June 8, 2016 | 0.8752 |
| March 8, 2016 | 0.8752 |
| ▸2015 |
2.77 EUR
|
| Dec. 7, 2015 | 0.6914 |
| Sept. 8, 2015 | 0.6914 |
| June 5, 2015 | 0.6914 |
| March 6, 2015 | 0.6914 |
| ▸2014 |
2.14 EUR
|
| Dec. 5, 2014 | 0.5339 |
| Sept. 5, 2014 | 0.5339 |
| June 6, 2014 | 0.5339 |
| March 7, 2014 | 0.5339 |
| ▸2013 |
1.65 EUR
|
| Dec. 6, 2013 | 0.4113 |
| Sept. 6, 2013 | 0.4113 |
| June 7, 2013 | 0.4113 |
| March 7, 2013 | 0.4113 |
| ▸2012 |
1.26 EUR
|
| Dec. 7, 2012 | 0.3151 |
| Sept. 7, 2012 | 0.3151 |
| June 7, 2012 | 0.3151 |
| Feb. 13, 2012 | 0.3151 |
| ▸2011 |
0.49 EUR
|
| Nov. 15, 2011 | 0.2451 |
| Aug. 16, 2011 | 0.2451 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Amgen Inc. | Jun 05, 2026 | Paid | 2.205504 EUR |
| Amgen Inc. | Mar 06, 2026 | Paid | 2.205504 EUR |
| Amgen Inc. | Dec 12, 2025 | Paid | 2.082976 EUR |
| Amgen Inc. | Sep 12, 2025 | Paid | 2.082976 EUR |
Community Discussion